Skip to main content
Premium Trial:

Request an Annual Quote

Gel Co., Axaron Bioscience, Spotfire


Gel Co. of San Francisco last week announced the ArrayBooster, a low-volume hybridization station for DNA and protein microarrays. The system is compatible with slide-based microarrays and has an active agitation feature based on surface acoustic waves. The product uses Advacards, a micro-agitation card with integrated pumps that cover the array and minimize the required sample volume. The company says the product will reduce incubation times and increase the specificity of hybridization and is suitable for the detection of low-expression genes. The product holds four incubation chambers that are controlled by one personal computer.


Axaron Bioscience launched Axaminer, a research and development service for drug discovery. Axaminer enables gene expression profiling at a cellular level and allows a detailed analysis of isolated cells. The Axaminer technology comprises four integrated modules: specific cell labeling; automated cell isolation using laser microdissection technology; isolation and amplification of picogram amounts of RNA; and transcription profiling.


Spotfire has released a new version of DecisionSite, with Analysis Builder, a tool for visual and interactive data analysis, and Poster, a collaboration tool.


The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.